Coherus BioSciences (CHRS) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.05 +2.94%
Revenue Growth %: +37.8%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
PBCO, SICP, MNSB, More
Revenue Growth %: +37.8%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
PBCO, SICP, MNSB, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $54.14 million versus the consensus estimate of $44.15 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy shares fall despite beating Q3 estimates
- Knowles (KN) Tops Q3 EPS by 2c; offers guidance
- South Plains Financial Inc. (SPFI) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
